INVESTOR ALERT: Investigation of Repros Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP

LOS ANGELES--(BUSINESS WIRE)--

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Repros Therapeutics Inc. (“Repros Therapeutics” or the “Company”) RPRX concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning the Company's business and financial prospects.

Please contact Lesley Portnoy, Esq., at (888) 773-9224 or (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

Repros Therapeutics is a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company is developing Androxal for the treatment of low testosterone due to secondary hypogonadism.

On September 26, 2014, the Company announced that it had been granted a Type B Pre-NDA meeting with the FDA in the first half of November 2014. According to the Company, Repros Therapeutics would seek guidance on its planned New Drug Application (NDA) for Androxal during the meeting. The press release also indicated that the Company believed that the NDA for Androxal would be filed around the end of 2014. However, on October 17, 2014, the Company revealed that the clinical information provided to the FDA was not sufficient for a Type B Pre-NDA meeting and that the November 2014 meeting with the FDA would be a Type C guidance meeting instead. Following this news, shares of Repros Therapeutics stock dropped nearly 40%, to a closing price of $3.61 per share on October 17, 2014, on heavy trading volume.

If you purchased Repros Therapeutics shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esq. of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, by toll-free telephone at (888) 773-9224 or by telephone at (310) 201-9150, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.